文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Clinical and biochemical features of atherogenic hyperlipidemias with different genetic basis: A comprehensive comparative study.

作者信息

Blokhina Anastasia V, Ershova Alexandra I, Kiseleva Anna V, Sotnikova Evgeniia A, Zharikova Anastasia A, Zaicenoka Marija, Vyatkin Yuri V, Ramensky Vasily E, Kutsenko Vladimir A, Litinskaya Olga A, Pokrovskaya Maria S, Shalnova Svetlana A, Meshkov Alexey N, Drapkina Oxana M

机构信息

Laboratory of Clinomics, National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Healthcare of the Russian Federation, Moscow, Russia.

Institute of Personalized Therapy and Prevention, National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Healthcare of the Russian Federation, Moscow, Russia.

出版信息

PLoS One. 2024 Dec 20;19(12):e0315693. doi: 10.1371/journal.pone.0315693. eCollection 2024.


DOI:10.1371/journal.pone.0315693
PMID:39705280
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11661581/
Abstract

Patients with genetically-based hyperlipidemias exhibit a wide phenotypic variability. Investigation of clinical and biochemical features is important for identifying genetically-based hyperlipidemias, determining disease prognosis, and initiating timely treatment. We analyzed genetic data from 3374 samples and compared clinical data, lipid levels (low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol, triglycerides, and lipoprotein (a)), frequency, age at onset of coronary heart disease (CHD), and the severity of carotid and femoral atherosclerosis (plaque number, maximum stenosis, total stenosis, maximum plaque height, and plaque score) among patients with familial hypercholesterolemia (FH), familial dysbetalipoproteinemia (FD), polygenic hypercholesterolemia (HCL), severe HCL, and those without lipid disorders (n = 324). FH patients exhibited the highest LDL-C (median 8.03 mmol/L, p < 0.001). FD patients had elevated triglyceride levels (median 4.10 mmol/L), lower LDL-C (median 3.57 mmol/L), and high-density lipoprotein cholesterol (median 1.03 mmol/L) compared to FH, polygenic HCL, and severe HCL, p < 0.05. FH and FD patients had similar early onset of CHD, with a median age of 44 and 40 years and comparable frequencies of 29.5% and 31.0%, respectively. They were more likely to develop CHD than subjects without lipid disorders (p = 0.042 and p < 0.001, respectively). Additionally, FH patients had higher a carotid plaque number, total carotid stenosis, and carotid plaque score. This study presents the first simultaneous comparison of clinical and biochemical features among FD, FH, polygenic, and severe HCL, along with the first comprehensive evaluation of carotid and femoral atherosclerosis ultrasound parameters in FD patients. The results highlight distinct phenotypic features unique to each hyperlipidemia analyzed and underscore FH and FD as the most atherogenic hyperlipidemias.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce9d/11661581/eff18ecab00b/pone.0315693.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce9d/11661581/665caf9bdfeb/pone.0315693.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce9d/11661581/613f0952c88e/pone.0315693.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce9d/11661581/980fa6dee8c0/pone.0315693.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce9d/11661581/dcd47d4c75d3/pone.0315693.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce9d/11661581/ea3e150264bf/pone.0315693.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce9d/11661581/0b81834c562e/pone.0315693.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce9d/11661581/eff18ecab00b/pone.0315693.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce9d/11661581/665caf9bdfeb/pone.0315693.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce9d/11661581/613f0952c88e/pone.0315693.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce9d/11661581/980fa6dee8c0/pone.0315693.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce9d/11661581/dcd47d4c75d3/pone.0315693.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce9d/11661581/ea3e150264bf/pone.0315693.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce9d/11661581/0b81834c562e/pone.0315693.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce9d/11661581/eff18ecab00b/pone.0315693.g007.jpg

相似文献

[1]
Clinical and biochemical features of atherogenic hyperlipidemias with different genetic basis: A comprehensive comparative study.

PLoS One. 2024-12-20

[2]
Beyond early LDL cholesterol lowering to prevent coronary atherosclerosis in familial hypercholesterolaemia.

Eur J Prev Cardiol. 2024-5-11

[3]
Greater preclinical atherosclerosis in treated monogenic familial hypercholesterolemia vs. polygenic hypercholesterolemia.

Atherosclerosis. 2017-5-13

[4]
Familial hypercholesterolemia: molecular, biochemical, and clinical characterization of a French-Canadian pediatric population.

Pediatrics. 1995-8

[5]
Lipoprotein-associated phospholipase A₂ activity is increased in patients with definite familial hypercholesterolemia compared with other forms of hypercholesterolemia.

Nutr Metab Cardiovasc Dis. 2018-5

[6]
Heterozygous familial hypercholesterolemia in children: low-density lipoprotein receptor mutational analysis and variation in the expression of plasma lipoprotein-lipid concentrations.

Atherosclerosis. 1996-9-27

[7]
Prevalence, clinical features and prognosis of familial hypercholesterolemia in Chinese Han patients with acute coronary syndrome after a coronary event: a retrospective observational study.

BMC Cardiovasc Disord. 2024-3-5

[8]
Clinical Implications of Monogenic Versus Polygenic Hypercholesterolemia: Long-Term Response to Treatment, Coronary Atherosclerosis Burden, and Cardiovascular Events.

J Am Heart Assoc. 2021-5-4

[9]
Evaluation of glycemic status and subclinical atherosclerosis in familial hypercholesterolemia subjects with or without LDL receptor mutation.

Cardiovasc Diabetol. 2025-3-20

[10]
Positive family history for coronary heart disease and 'midband lipoproteins' are potential risk factors of carotid atherosclerosis in familial hypercholesterolemia.

Atherosclerosis. 2002-2

引用本文的文献

[1]
Genetic and Metabolic Factors of Familial Dysbetalipoproteinemia Phenotype: Insights from a Cross-Sectional Study.

Int J Mol Sci. 2025-7-30

本文引用的文献

[1]
Spectrum and Prevalence of Rare Variants and Their Association with Familial Dysbetalipoproteinemia.

Int J Mol Sci. 2024-11-25

[2]
Prevalence of Dysbetalipoproteinemia in the UK Biobank According to Different Diagnostic Criteria.

J Clin Endocrinol Metab. 2025-2-18

[3]
Applicability of Diagnostic Criteria and High Prevalence of Familial Dysbetalipoproteinemia in Russia: A Pilot Study.

Int J Mol Sci. 2023-8-24

[4]
International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia.

Nat Rev Cardiol. 2023-12

[5]
Phenotypic vs. genetic cascade screening for familial hypercholesterolemia: A case report.

Front Cardiovasc Med. 2022-8-25

[6]
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement.

Eur Heart J. 2022-10-14

[7]
Establishing the relationship between familial dysbetalipoproteinemia and genetic variants in the APOE gene.

Clin Genet. 2022-10

[8]
Lipoprotein(a) as Part of the Diagnosis of Clinical Familial Hypercholesterolemia.

Curr Atheroscler Rep. 2022-4

[9]
Underdiagnosis of familial hypercholesterolaemia: innovation is overdue.

Eur Heart J. 2022-9-7

[10]
The Clinical Genome Resource (ClinGen) Familial Hypercholesterolemia Variant Curation Expert Panel consensus guidelines for LDLR variant classification.

Genet Med. 2022-2

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索